AstraZeneca (AZN.US) has significantly extended the life of cancer patients with its groundbreaking immunotherapy combination Imfinzi.

Imfinzi is a humanized monoclonal antibody.

Zhitong FinanceFeb 14 18:38 ET

Express News | Trump Order Halts Funding For School Covid Vaccine Mandates

BenzingaFeb 14 14:12 ET

AstraZeneca Reports Positive Results for Imfinzi MIBC Regimen

Seeking AlphaFeb 14 13:30 ET

AstraZeneca's Bladder Cancer Combo Therapy Shows Efficacy in Late-stage Study

MT NewswiresFeb 14 11:47 ET

Fund Update: UBS AM, a Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC Opened a $12.0M Position in $AZN Stock

Quiver QuantitativeFeb 14 11:47 ET

AstraZeneca's IMFINZI Perioperative Regimen Improved Event-Free Survival And Overall Survival Across Muscle-Invasive Bladder Cancer Patients Regardless Of Complete Pathology Response Status In Post-Hoc Exploratory Analysis Of Niagara Phase III Trial

BenzingaFeb 14 11:12 ET